2325 GMT - Cochlear shakes off its bear at UBS thanks to the 14% share-price dive that followed the hearing-implant maker's 1H result. Analyst Laura Sutcliffe raises her recommendation on the Australia-listed stock to neutral from sell, telling clients in a note that the result wasn't as bad as it looked. She isn't totally convinced by the company's expectation of 10% implant unit growth in the June half, calling it a big ask. However, she sees Cochlear's confidence in such a growth rate going forward as important. UBS lifts its target price 5.6% to A$285.00. Shares are up 2.6% at A$269.64. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 16, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。